Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05475171 · ClinicalTrials.gov registry record · Phase 2
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
A Phase 2 study of Cervical Cancer and Metastatic Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05475171: Recruiting Phase 2 study of Cervical Cancer and Metastatic Cancer, sponsored by M.D. Anderson Cancer Center.
NCT05475171 is a Phase 2 study of Cervical Cancer and Metastatic Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05475171, a Phase 2 study of Cervical Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Conditions Studied
Interventions
- DRUG Lorigerlimab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT05475171 shows while recruiting
NCT05475171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lorigerlimab is the first listed.
NCT05475171 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05475171 about?
NCT05475171 is a clinical study titled "Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)". To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
What is the current status of trial NCT05475171?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-12-13. Estimated completion is 2026-06-30.
What conditions does trial NCT05475171 study?
This clinical trial studies the following conditions: Cervical Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT05475171?
The interventions under investigation include: Lorigerlimab (DRUG).
Who is sponsoring clinical trial NCT05475171?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05475171 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05475171's enrollment target sits among peer trials
40 107th of 144 higher than 33 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI